| Income Statement | 2025-06-30 | 2025-03-31 | 2024-06-30 | |
|---|---|---|---|---|
| Interest expense attributable to amortization of discount | 12,639 | 12,639 | - | |
| Total other income (expense), net | -126,536 | 93,995 | -22,154 | |
| Net loss before income taxes | -167,292 | -19,354 | - | |
| Income tax provision | 0 | - | - | |
| Net loss | -167,292 | -19,354 | -130,120 | |
| Net loss per common share - basic | -0.01 | 0 | -0.03 | |
| Net loss per common share - diluted | -0.01 | 0 | -0.03 | |
| Number of weighted average shares - basic | 23,752,506 | 21,554,704 | 4,213,611 | |
| Number of weighted average shares - diluted | 23,752,506 | 21,554,704 | 4,213,611 | |
Regen BioPharma Inc (RGBP)
Regen BioPharma Inc (RGBP)